Author: Modrak, M.; Burkner, P.-C.; Sieger, T.; Slisz, T.; Vasakova, M.; Meseznikov, G.; Casas-Mendez, L. F.; Vajter, J.; Taborsky, J.; Kubricht, V.; Suk, D.; Horejsek, J.; Jedlicka, M.; Mifkova, A.; Jaros, A.; Kubiska, M.; Vachalova, J.; Sin, R.; Veverkova, M.; Pospisil, Z.; Vohryzkova, J.; Pokrievkova, R.; Hrusak, K.; Christozova, K.; Leos-Barajas, V.; Fiser, K.; Hyanek, T.
Title: Detailed disease progression of 213 patients hospitalized with Covid-19 in the Czech Republic: An exploratory analysis Cord-id: wswk7c2h Document date: 2020_12_4
ID: wswk7c2h
Snippet: We collected a multi-centric retrospective dataset of patients (N = 213) who were admitted to ten hospitals in Czech Republic and tested positive for SARS-CoV-2. The dataset contains baseline patient characteristics, breathing support required, pharmacological treatment received and multiple markers on daily resolution. Patients in the dataset were treated with hydroxychloroquine (N = 108), azithromycin (N = 72), favipiravir (N = 9), convalescent plasma (N = 7), dexamethasone (N = 4) and remdesi
Document: We collected a multi-centric retrospective dataset of patients (N = 213) who were admitted to ten hospitals in Czech Republic and tested positive for SARS-CoV-2. The dataset contains baseline patient characteristics, breathing support required, pharmacological treatment received and multiple markers on daily resolution. Patients in the dataset were treated with hydroxychloroquine (N = 108), azithromycin (N = 72), favipiravir (N = 9), convalescent plasma (N = 7), dexamethasone (N = 4) and remdesivir (N = 3), often in combination. Most patients were admitted during the first wave of the epidemic. To explore association between treatments and patient outcomes we performed multiverse analysis, observing how the conclusions change between defensible choices of statistical model, predictors included in the model and other analytical degrees of freedom. Weak evidence to constrain the potential efficacy of azithromycin and favipiravir can be extracted from the data. Additionally, we performed external validation of several proposed prognostic models for Covid-19 severity showing that they mostly perform unsatisfactorily on our dataset.
Search related documents:
Co phrase search for related documents- acute sars respiratory syndrome coronavirus and additional detail: 1
- acute sars respiratory syndrome coronavirus and additional structure: 1, 2, 3, 4
- acute sars respiratory syndrome coronavirus and admission day: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute sars respiratory syndrome coronavirus and loading dose: 1, 2
- acute sars respiratory syndrome coronavirus and logistic regression model: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute sars respiratory syndrome coronavirus and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute sars respiratory syndrome coronavirus and lopinavir ritonavir benefit: 1, 2
- additional adjustment and admission day: 1, 2
- admission day and loading dose: 1, 2
- admission day and logistic regression model: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
- admission day and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
- loading dose and logistic regression model: 1
- loading dose and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7
- logistic regression model and lopinavir ritonavir: 1, 2, 3, 4, 5, 6
Co phrase search for related documents, hyperlinks ordered by date